• Lunai Bioworks asked Nasdaq to immediately suspend trading in its common stock while regulators review trading records tied to pending litigation.
• The request cites court-ordered discovery in Lunai Bioworks v. Seven Points Capital, Case No. 1:26-cv-00549-CFC, in Delaware federal court.
• Submission alleges substantial short selling, locate deficiencies, concentrated failures to deliver that could indicate an unfair or disorderly market.
• Nasdaq has not decided on the request; the filing says the request itself does not halt trading.
• The lawsuit remains pending; the allegations have not been adjudicated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001333), on October 09, 2026, and is solely responsible for the information contained therein.